Europe buys 500,000 courses of Gilead's remdesivir amid supply worries

Gilead Sciences said on Thursday it had agreed to sell Europe up to 500,0000 courses of its antiviral drug remdesivir, as the continent scrambles to shore up supplies of one of only two drugs approved to treat Covid-19 patients.

The deal will cover purchases of the drug for the next six months for the 27-nation European Union, Britain, six Balkan countries and the other European Economic Area countries - Iceland, Liechtenstein and Norway. Several European countries have said they are experiencing shortages of the drug, whose global.....

This article is no longer available in our repository.

There could be multiple reasons for this.